-
1
-
-
70349545970
-
Iron overload and toxicity: The hidden risk of multiple blood transfusions
-
Shander A, Cappellini MD, Goodnough L. Iron overload and toxicity: the hidden risk of multiple blood transfusions. Vox Sang 2009; 97: 185-97.
-
(2009)
Vox Sang
, vol.97
, pp. 185-197
-
-
Shander, A.1
Cappellini, M.D.2
Goodnough, L.3
-
3
-
-
34248569916
-
Retrospective nationwide survey of Japanese patients with transfusion-dependent MDS and aplastic anemia highlights the negative impact of iron overload on morbidity/mortality
-
DOI 10.1111/j.1600-0609.2007.00842.x
-
Takatoku M, Uchiyama T, Okamoto S, et al. Retrospective nationwide survey of Japanese patients with transfusion-dependent MDS and aplastic anemia highlights the negative impact of iron overload on morbidity/mortality. Eur J Haematol 2007; 78: 487-94. (Pubitemid 46753591)
-
(2007)
European Journal of Haematology
, vol.78
, Issue.6
, pp. 487-494
-
-
Takatoku, M.1
Uchiyama, T.2
Okamoto, S.3
Kanakura, Y.4
Sawada, K.5
Tomonaga, M.6
Nakao, S.7
Nakahata, T.8
Harada, M.9
Murate, T.10
Ozawa, K.11
-
5
-
-
0034601375
-
Hepatic iron concentration and total body iron stores in thalassemia major
-
DOI 10.1056/NEJM200008033430503
-
Angelucci E, Brittenham GM, McLaren CE, et al. Hepatic iron concentration and total body iron stores in thalassemia major. N Engl J Med 2000; 343: 327-31. (Pubitemid 30616698)
-
(2000)
New England Journal of Medicine
, vol.343
, Issue.5
, pp. 327-331
-
-
Angelucci, E.1
Brittenham, G.M.2
McLaren, C.E.3
Ripalti, M.4
Baronciani, D.5
Giardini, C.6
Galimberti, M.7
Polchi, P.8
Lucarelli, G.9
-
6
-
-
14544271816
-
LPI-labile plasma iron in iron overload
-
DOI 10.1016/j.beha.2004.10.003, PII S1521692604001264
-
Cabantchik ZI, Breuer W, Zanninelli G, Cianciulli P. LPI-labile plasma iron in iron overload. Best Prat Res Clin Haematol 2005; 18: 277-87. (Pubitemid 40298370)
-
(2005)
Best Practice and Research: Clinical Haematology
, vol.18
, Issue.2 SPEC. ISS.
, pp. 277-287
-
-
Cabantchik, Z.I.1
Breuer, W.2
Zanninelli, G.3
Cianciulli, P.4
-
7
-
-
78651287827
-
Iron overload in MDS-pathophysiology, diagnosis, and complications
-
Gattermann N, Rachmilewitz EA. Iron overload in MDS-pathophysiology, diagnosis, and complications. Ann Hematol 2011; 90: 1-10.
-
(2011)
Ann Hematol
, vol.90
, pp. 1-10
-
-
Gattermann, N.1
Rachmilewitz, E.A.2
-
8
-
-
20844460608
-
Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine
-
Borgna-Pignatti C, Rugolotto S, De Stefano P, et al. Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine. Haematologica 2004; 89: 1187-93. (Pubitemid 39390442)
-
(2004)
Haematologica
, vol.89
, Issue.10
, pp. 1187-1193
-
-
Borgna-Pignatti, C.1
Rugolotto, S.2
De Stefano, P.3
Zhao, H.4
Cappellini, M.D.5
Del, V.G.C.6
Romeo, M.A.7
Forni, G.L.8
Gamberini, M.R.9
Ghilardi, R.10
Piga, A.11
Cnaan, A.12
-
9
-
-
0033760134
-
Hepatic iron concentration combined with long-term monitoring of serum ferritin to predict complications of iron overload in thalassaemia major
-
Telfer PT, Prestcott E, Holden S, et al. Hepatic iron concentration combined with long-term monitoring of serum ferritin to predict complications of iron overload in thalassaemia major. Br J Haematol 2000; 110: 971-7.
-
(2000)
Br J Haematol
, vol.110
, pp. 971-977
-
-
Telfer, P.T.1
Prestcott, E.2
Holden, S.3
-
10
-
-
10444255328
-
Synergic effect of chronic hepatitis C infection and beta thalassemia major with marked hepatic iron overload on liver fibrosis: A retrospective crosssectional study
-
Ardalan FA, Osquei MR, Toosi MN, Irvanloo G. Synergic effect of chronic hepatitis C infection and beta thalassemia major with marked hepatic iron overload on liver fibrosis: a retrospective crosssectional study. BMC Gastroenterol 2004; 4: 17.
-
(2004)
BMC Gastroenterol
, vol.4
, pp. 17
-
-
Ardalan, F.A.1
Osquei, M.R.2
Toosi, M.N.3
Irvanloo, G.4
-
11
-
-
0036660189
-
Effects of iron overload and hepatitis C virus positivity in determining progression of liver fibrosis in thalassemia following bone marrow transplantation
-
DOI 10.1182/blood.V100.1.17
-
Angelucci E, Muretto P, Nicolucci A, et al. Effects of iron overload and hepatitis C virus positivity in determining progression of liver fibrosis in thalassemia following bone marrow transplantation. Blood 2002; 100: 17-21. (Pubitemid 35177422)
-
(2002)
Blood
, vol.100
, Issue.1
, pp. 17-21
-
-
Angelucci, E.1
Muretto, P.2
Nicolucci, A.3
Baronciani, D.4
Erer, B.5
Gaziev, J.6
Ripalti, M.7
Sodani, P.8
Tomassoni, S.9
Visani, G.10
Lucarelli, G.11
-
13
-
-
0037125595
-
Comparison of effects of oral deferiprone and subcutaneous desferrioxamine on myocardial iron concentrations and ventricular function in beta-thalassaemia
-
DOI 10.1016/S0140-6736(02)09740-4
-
Anderson LJ, Wonke B, Prescott E, et al. Comparison of effects of oral deferiprone and subcutaneous desferrioxamine on myocardial iron concentrations and ventricular function in beta-thalassaemia. Lancet 2002; 360: 516-20. (Pubitemid 35232104)
-
(2002)
Lancet
, vol.360
, Issue.9332
, pp. 516-520
-
-
Anderson, L.J.1
Wonke, B.2
Prescott, E.3
Holden, S.4
Walker, J.M.5
Pennell, D.J.6
-
14
-
-
57049104663
-
Cardiac iron across different transfusiondependent diseases
-
Wood JC. Cardiac iron across different transfusiondependent diseases. Blood Rev 2008; 22 (Suppl 2):S14-S21.
-
(2008)
Blood Rev
, vol.22
, Issue.SUPPL. 2
-
-
Wood, J.C.1
-
15
-
-
33646387405
-
Randomized controlled trial of deferiprone or deferoxamine in beta-thalassemia major patients with asymptomatic myocardial siderosis
-
Pennell DJ, Berdoukas V, Karagiorga M, et al. Randomized controlled trial of deferiprone or deferoxamine in beta-thalassemia major patients with asymptomatic myocardial siderosis. Blood 2006; 107: 3738-44.
-
(2006)
Blood
, vol.107
, pp. 3738-3744
-
-
Pennell, D.J.1
Berdoukas, V.2
Karagiorga, M.3
-
16
-
-
77950617863
-
Efficacy of deferasirox in reducing and preventing cardiac iron overload in beta-thalassemia
-
Pennell DJ, Porter JB, Cappellini MD, et al. Efficacy of deferasirox in reducing and preventing cardiac iron overload in beta-thalassemia. Blood 2010; 115: 2364-71.
-
(2010)
Blood
, vol.115
, pp. 2364-2371
-
-
Pennell, D.J.1
Porter, J.B.2
Cappellini, M.D.3
-
17
-
-
77953779950
-
The effect of deferasirox on cardiac iron in thalassemia major: Impact of total body iron stores
-
Wood JC, Kang BP, Thompson A, et al. The effect of deferasirox on cardiac iron in thalassemia major: impact of total body iron stores. Blood 2010; 116: 537-43.
-
(2010)
Blood
, vol.116
, pp. 537-543
-
-
Wood, J.C.1
Kang, B.P.2
Thompson, A.3
-
18
-
-
72449177984
-
Cardiac T2*magnetic resonance for prediction of cardiac complications in thalassemia major
-
Kirk P, Roughton M, Porter JB, et al. Cardiac T2*magnetic resonance for prediction of cardiac complications in thalassemia major. Circulation 2009; 120: 1961-8.
-
(2009)
Circulation
, vol.120
, pp. 1961-1968
-
-
Kirk, P.1
Roughton, M.2
Porter, J.B.3
-
19
-
-
0028059813
-
Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia major
-
DOI 10.1056/NEJM199409013310902
-
Brittenham GM, Griffith PM, Nienhuis AW, et al. Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia major. N Engl J Med 1994; 331: 567-73. (Pubitemid 24265698)
-
(1994)
New England Journal of Medicine
, vol.331
, Issue.9
, pp. 567-573
-
-
Brittenham, G.M.1
Griffith, P.M.2
Nienhuis, A.W.3
McLaren, C.E.4
Young, N.S.5
Tucker, E.E.6
Allen, C.J.7
Farrell, D.E.8
Harris, J.W.9
-
20
-
-
3042746877
-
Value of sequential monitoring of left ventricular ejection fraction in the management of thalassemia major
-
DOI 10.1182/blood-2003-08-2841
-
Davis BA, O'Sullivan C, Jarritt PH, Porter JB. Value of sequential monitoring of left ventricular ejection fraction in the management of thalassemia major. Blood 2004; 104: 263-9. (Pubitemid 38879867)
-
(2004)
Blood
, vol.104
, Issue.1
, pp. 263-269
-
-
Davis, B.A.1
O'Sullivan, C.2
Jarritt, P.H.3
Porter, J.B.4
-
21
-
-
76549140036
-
Late cardiac complications of chronic, severe, refractory anemia with hemochromatosis
-
Engle MA, Erlandson M, Smith CH. Late cardiac complications of chronic, severe, refractory anemia with hemochromatosis. Circulation 1964; 30: 698-705.
-
(1964)
Circulation
, vol.30
, pp. 698-705
-
-
Engle, M.A.1
Erlandson, M.2
Smith, C.H.3
-
22
-
-
0028086414
-
Survival in medically treated patients with homozygous β-thalassemia
-
DOI 10.1056/NEJM199409013310903
-
Olivieri NF, Nathan DG, MacMillan JH, et al. Survival in medically treated patients with homozygous betathalassemia. N Engl J Med 1994; 331: 574-8. (Pubitemid 24265699)
-
(1994)
New England Journal of Medicine
, vol.331
, Issue.9
, pp. 574-578
-
-
Olivieri, N.F.1
Nathan, D.G.2
Macmillan, J.H.3
Wayne, A.S.4
Liu, P.P.5
Mcgee, A.6
Martin, M.7
Koren, G.8
Cohen, A.R.9
-
23
-
-
0031001278
-
Iron-chelating therapy and the treatment of thalassemia
-
Olivieri NF, Brittenham GM. Iron-chelating therapy and the treatment of thalassemia. Blood 1997; 89: 739-61. (Pubitemid 27121266)
-
(1997)
Blood
, vol.89
, Issue.3
, pp. 739-761
-
-
Olivieri, N.F.1
Brittenham, G.M.2
-
24
-
-
33646414765
-
A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia
-
Cappellini MD, Cohen A, Piga A, et al. A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia. Blood 2006; 107: 3455-62.
-
(2006)
Blood
, vol.107
, pp. 3455-3462
-
-
Cappellini, M.D.1
Cohen, A.2
Piga, A.3
-
25
-
-
0021225166
-
Depletion of excessive liver iron stores with desferrioxamine
-
Cohen A, Martin M, Schwartz E. Depletion of excessive liver iron stores with desferrioxamine. Br J Haematol 1984; 58: 369-73. (Pubitemid 14002111)
-
(1984)
British Journal of Haematology
, vol.58
, Issue.2
, pp. 369-373
-
-
Cohen, A.1
Martin, M.2
Schwartz, E.3
-
26
-
-
12544260252
-
Prevalence of endocrine complications and short stature in patients with thalassaemia major: A multicenter study by the Thalassaemia International Federation (TIF)
-
Thalassaemia International Federation Study Group on Growth and Endocrine Complications in Thalassaemia
-
De Sanctis V, Eleftheriou A, Malaventura C. Thalassaemia International Federation Study Group on Growth and Endocrine Complications in Thalassaemia. Prevalence of endocrine complications and short stature in patients with thalassaemia major: a multicenter study by the Thalassaemia International Federation (TIF). Pediatr Endocrinol Rev 2004; 2 (Suppl 2): 249-55.
-
(2004)
Pediatr Endocrinol Rev
, vol.2
, Issue.SUPPL. 2
, pp. 249-255
-
-
De Sanctis, V.1
Eleftheriou, A.2
Malaventura, C.3
-
27
-
-
0034651775
-
Long-term outcome of continuous 24-hour deferoxamine infusion via indwelling intravenous catheters in high-risk β-thalassemia
-
Davis BA, Porter JB. Long-term outcome of continuous 24-hour deferoxamine infusion via indwelling intravenous catheters in high-risk beta-thalassemia. Blood 2000; 95: 1229-36. (Pubitemid 30099831)
-
(2000)
Blood
, vol.95
, Issue.4
, pp. 1229-1236
-
-
Davis, B.A.1
Porter, J.B.2
-
28
-
-
7944230624
-
Myocardial iron clearance during reversal of siderotic cardiomyopathy with intravenous desferrioxamine: A prospective study using T2* cardiovascular magnetic resonance
-
DOI 10.1111/j.1365-2141.2004.05202.x
-
Anderson LJ, Westwood MA, Holden S, et al. Myocardial iron clearance during reversal of siderotic cardiomyopathy with intravenous desferrioxamine: a prospective study using T2*cardiovascular magnetic resonance. Br J Haematol 2004; 127: 348-55. (Pubitemid 39468951)
-
(2004)
British Journal of Haematology
, vol.127
, Issue.3
, pp. 348-355
-
-
Anderson, L.J.1
Westwood, M.A.2
Holden, S.3
Davis, B.4
Prescott, E.5
Wonke, B.6
Porter, J.B.7
Walker, J.M.8
Pennell, D.J.9
-
29
-
-
29744445267
-
Recent insights into interactions of deferoxamine with cellular and plasma iron pools: Implications for clinical use
-
DOI 10.1196/annals.1345.018
-
Porter JB, Rafique R, Srichairatanakool S, et al. Recent insights into interactions of deferoxamine with cellular and plasma iron pools: implications for clinical use. Ann N Y Acad Sci 2005; 1054: 155-68. (Pubitemid 43031020)
-
(2005)
Annals of the New York Academy of Sciences
, vol.1054
, pp. 155-168
-
-
Porter, J.B.1
Rafique, R.2
Srichairatanakool, S.3
Davis, B.A.4
Shah, F.T.5
Hair, T.6
Evans, P.7
-
30
-
-
10744230223
-
Effectiveness and safety of ICL670 in iron-loaded patients with thalassaemia: A randomised, double-blind, placebo-controlled, dose-escalation trial
-
DOI 10.1016/S0140-6736(03)13309-0
-
Nisbet-Brown E, Olivieri NF, Giardina PJ, et al. Effectiveness and safety of ICL670 in iron-loaded patients with thalassaemia: a randomised, doubleblind, placebo-controlled, dose-escalation trial. Lancet 2003; 361: 1597-602. (Pubitemid 36578996)
-
(2003)
Lancet
, vol.361
, Issue.9369
, pp. 1597-1602
-
-
Nisbet-Brown, E.1
Olivieri, N.F.2
Giardina, P.J.3
Grady, R.W.4
Neufeld, E.J.5
Sechaud, R.6
Krebs-Brown, A.J.7
Anderson, J.R.8
Alberti, D.9
Sizer, K.C.10
Nathan, D.G.11
-
31
-
-
34548708556
-
Consequences and costs of noncompliance with iron chelation therapy in patients with transfusion-dependent thalassemia: A literature review
-
DOI 10.1111/j.1537-2995.2007.01416.x
-
Delea TE, Edelsberg J, Sofrygin O, et al. Consequences and costs of noncompliance with iron chelation therapy in patients with transfusion-dependent thalassemia: a literature review. Transfusion 2007; 47: 1919-29. (Pubitemid 47438560)
-
(2007)
Transfusion
, vol.47
, Issue.10
, pp. 1919-1929
-
-
Delea, T.E.1
Edelsberg, J.2
Sofrygin, O.3
Thomas, S.K.4
Baladi, J.-F.5
Phatak, P.D.6
Coates, T.D.7
-
32
-
-
33646407268
-
Cardiac morbidity and mortality in deferoxamineor deferiprone-treated patients with thalassemia major
-
Borgna-Pignatti C, Cappellini MD, De Stefano P, et al. Cardiac morbidity and mortality in deferoxamineor deferiprone-treated patients with thalassemia major. Blood 2006; 107: 3733-7.
-
(2006)
Blood
, vol.107
, pp. 3733-3737
-
-
Borgna-Pignatti, C.1
Cappellini, M.D.2
De Stefano, P.3
-
33
-
-
80355129916
-
A pilot trial of deferiprone for neurodegeneration with brain iron accumulation
-
Abbruzzese G, Cossu G, Balocco M, et al. A pilot trial of deferiprone for neurodegeneration with brain iron accumulation. Haematologica 2011; 96: 1708-11.
-
(2011)
Haematologica
, vol.96
, pp. 1708-1711
-
-
Abbruzzese, G.1
Cossu, G.2
Balocco, M.3
-
34
-
-
34347370842
-
Selective iron chelation in Friedreich ataxia: Biologic and clinical implications
-
DOI 10.1182/blood-2006-12-065433
-
Boddaert N, Le Quan Sang KH, Rötig A, et al. Selective iron chelation in Friedreich ataxia: biologic and clinical implications. Blood 2007; 110: 401-8. (Pubitemid 47026862)
-
(2007)
Blood
, vol.110
, Issue.1
, pp. 401-408
-
-
Boddaert, N.1
Sang, K.H.L.Q.2
Rotig, A.3
Leroy-Willig, A.4
Gallet, S.5
Brunelle, F.6
Sidi, D.7
Thalabard, J.-C.8
Munnich, A.9
Cabantchik, Z.I.10
-
35
-
-
38949197818
-
Redistribution of accumulated cell iron: A modality of chelation with therapeutic implications
-
DOI 10.1182/blood-2007-07-102335
-
Sohn YS, Breuer W, Munnich A, Cabantchik ZI. Redistribution of accumulated cell iron: a modality of chelation with therapeutic implications. Blood 2008; 111: 1690-9. (Pubitemid 351213461)
-
(2008)
Blood
, vol.111
, Issue.3
, pp. 1690-1699
-
-
Sohn, Y.-S.1
Breuer, W.2
Munnich, A.3
Cabantchik, Z.I.4
-
36
-
-
84355166625
-
The challenges of adherence and persistence with iron chelation therapy
-
Porter JB, Evangeli M, El-Beshlway A. The challenges of adherence and persistence with iron chelation therapy. Int J Hematol 2011; 94: 453-60.
-
(2011)
Int J Hematol
, vol.94
, pp. 453-460
-
-
Porter, J.B.1
Evangeli, M.2
El-Beshlway, A.3
-
37
-
-
0034928342
-
Exploring the "iron shuttle" hypothesis in chelation therapy: Effects of combined deferoxamine and deferiprone treatment in hypertransfused rats with labeled iron stores and in iron-loaded rat heart cells in culture
-
DOI 10.1067/mlc.2001.116487
-
Link G, Konijn AM, Breuer W, et al. Exploring the "iron shuttle" hypothesis in chelation therapy: effects of combined deferoxamine and deferiprone treatment in hypertransfused rats with labeled iron stores and in iron-loaded rat heart cells in culture. J Lab Clin Med 2001; 138: 130-8. (Pubitemid 32696277)
-
(2001)
Journal of Laboratory and Clinical Medicine
, vol.138
, Issue.2
, pp. 130-138
-
-
Link, G.1
Konijn, A.M.2
Breuer, W.3
Cabantchik, Z.I.4
Hershko, C.5
-
38
-
-
77955379581
-
Mechanisms for the shuttling of plasma non-transferrin-bound iron (NTBI) onto deferoxamine by deferiprone
-
Evans P, Kayyali R, Hider RC, et al. Mechanisms for the shuttling of plasma non-transferrin-bound iron (NTBI) onto deferoxamine by deferiprone. Transl Res 2010; 156: 55-67.
-
(2010)
Transl Res
, vol.156
, pp. 55-67
-
-
Evans, P.1
Kayyali, R.2
Hider, R.C.3
-
39
-
-
0042943205
-
Safety and effectiveness of long-term therapy with the oral iron chelator deferiprone
-
DOI 10.1182/blood-2002-10-3280
-
Cohen AR, Galanello R, Piga A, et al. Safety and effectiveness of long-term therapy with the oral iron chelator deferiprone. Blood 2003; 102: 1583-7. (Pubitemid 37022545)
-
(2003)
Blood
, vol.102
, Issue.5
, pp. 1583-1587
-
-
Cohen, A.R.1
Galanello, R.2
Piga, A.3
De Sanctis, V.4
Tricta, F.5
-
40
-
-
34248635452
-
Fatal agranulocytosis after deferiprone therapy in a child with Diamond-Blackfan anemia
-
DOI 10.1182/blood-2007-02-065805
-
Henter JI, Karlén J. Fatal agranulocytosis after deferiprone therapy in a child with Diamond-Blackfan anemia. Blood 2007; 109: 5157-9. (Pubitemid 46890530)
-
(2007)
Blood
, vol.109
, Issue.12
, pp. 5157-5159
-
-
Henter, J.-I.1
Karlen, J.2
-
41
-
-
0033034080
-
1)
-
DOI 10.1007/s002280050584
-
Addis A, Loebstein R, Koren G, Einarson TR. Metaanalytic review of the clinical effectiveness of oral deferiprone (L1). Eur J Clin Pharmacol 1999; 55: 1-6. (Pubitemid 29144092)
-
(1999)
European Journal of Clinical Pharmacology
, vol.55
, Issue.1
, pp. 1-6
-
-
Addis, A.1
Loebstein, R.2
Koren, G.3
Einarson, T.R.4
-
42
-
-
27544480823
-
Safety and effectiveness of 100 mg/kg/day deferiprone in patients with thalassemia major: A two-year study
-
DOI 10.1159/000087888
-
Taher A, Sheikh-Taha M, Sharara A, et al. Safety and effectiveness of 100 mg/kg/day deferiprone in patients with thalassemia major: a two-year study. Acta Haematol 2005; 114: 146-9. (Pubitemid 41540337)
-
(2005)
Acta Haematologica
, vol.114
, Issue.3
, pp. 146-149
-
-
Taher, A.1
Sheikh-Taha, M.2
Sharara, A.3
Inati, A.4
Koussa, S.5
Ellis, G.6
Dhillon, A.P.7
Hoffbrand, A.V.8
-
43
-
-
0038187626
-
Comparative effects of deferiprone and deferoxamine on survival and cardiac disease in patients with thalassemia major: A retrospective analysis
-
Piga A, Gaglioti C, Fogliacco E, Tricta F. Comparative effects of deferiprone and deferoxamine on survival and cardiac disease in patients with thalassemia major: a retrospective analysis. Haematologica 2003; 88: 489-96. (Pubitemid 36648438)
-
(2003)
Haematologica
, vol.88
, Issue.5
, pp. 489-496
-
-
Piga, A.1
Gaglioti, C.2
Fogliacco, E.3
Tricta, F.4
-
44
-
-
80053488289
-
Effect of deferiprone or deferoxamine on right ventricular function in thalassemia major patients with myocardial iron overload
-
Smith GC, Alpendurada F, Carpenter JP, et al. Effect of deferiprone or deferoxamine on right ventricular function in thalassemia major patients with myocardial iron overload. J Cardiovasc Magn Reson 2011; 13: 34.
-
(2011)
J Cardiovasc Magn Reson
, vol.13
, pp. 34
-
-
Smith, G.C.1
Alpendurada, F.2
Carpenter, J.P.3
-
45
-
-
70349567584
-
The efficacy of iron chelator regimes in reducing cardiac and hepatic iron in patients with thalassaemia major: A clinical observational study
-
Berdoukas V, Chouliaras G, Moraitis P, et al. The efficacy of iron chelator regimes in reducing cardiac and hepatic iron in patients with thalassaemia major: a clinical observational study. J Cardiovasc Magn Reson 2009; 11: 20.
-
(2009)
J Cardiovasc Magn Reson
, vol.11
, pp. 20
-
-
Berdoukas, V.1
Chouliaras, G.2
Moraitis, P.3
-
46
-
-
0942298725
-
Comparative Efficacy of Desferrioxamine, Deferiprone and in Combination on Iron Chelation in Thalassemic Children
-
Gomber S, Saxena R, Madan N. Comparative efficacy of desferrioxamine, deferiprone and in combination on iron chelation in thalassemic children. Indian Pediatr 2004; 41: 21-7. (Pubitemid 38139865)
-
(2004)
Indian Pediatrics
, vol.41
, Issue.1
, pp. 21-27
-
-
Gomber, S.1
Saxena, R.2
Madan, N.3
-
47
-
-
33748783066
-
A prospective randomized controlled trial on the safety and efficacy of alternating deferoxamine and deferiprone in the treatment of iron overload in patients with thalassemia
-
Galanello R, Kattamis A, Piga A, et al. A prospective randomized controlled trial on the safety and efficacy of alternating deferoxamine and deferiprone in the treatment of iron overload in patients with thalassemia. Haematologica 2006; 91: 1241-3. (Pubitemid 44408435)
-
(2006)
Haematologica
, vol.91
, Issue.9
, pp. 1241-1243
-
-
Galanello, R.1
Kattamis, A.2
Piga, A.3
Fischer, R.4
Leoni, G.5
Ladis, V.6
Voi, V.7
Lund, U.8
Tricta, F.9
-
48
-
-
37049033278
-
A randomized controlled 1-year study of daily deferiprone plus twice weekly desferoxamine compared with daily deferiprone monotherapy in patients with thalassemia major
-
DOI 10.3324/haematol.11414
-
Aydinok Y, Ulger Z, Nart D, et al. A randomized controlled 1-year study of daily deferiprone plus twice weekly desferrioxamine compared with daily deferiprone monotherapy in patients with thalassemia major. Haematologica 2007; 92: 1599-606. (Pubitemid 350248238)
-
(2007)
Haematologica
, vol.92
, Issue.12
, pp. 1599-1606
-
-
Aydinok, Y.1
Ulger, Z.2
Nart, D.3
Terzi, A.4
Cetiner, N.5
Ellis, G.6
Zimmermann, A.7
Manz, C.8
-
49
-
-
33646677440
-
Combined theraphy with desferrioxamine and deferiprone in beta thalassemia major patients transfusional iron overload
-
Daar S, Pathare AV. Combined theraphy with desferrioxamine and deferiprone in beta thalassemia major patients transfusional iron overload. An Hematol 2006; 85: 315-6.
-
(2006)
An Hematol
, vol.85
, pp. 315-316
-
-
Daar, S.1
Pathare, A.V.2
-
50
-
-
44449104925
-
Iron chelation in thalassemia: Combined or monotherapy? The Egyptian experience
-
El-Beshlaway A, Manz C, Naja M, et al. Iron chelation in thalassemia: combined or monotherapy? The Egyptian experience. Ann Hematol 2008; 87: 545-50.
-
(2008)
Ann Hematol
, vol.87
, pp. 545-550
-
-
El-Beshlaway, A.1
Manz, C.2
Naja, M.3
-
51
-
-
34247103036
-
A randomized, placebo-controlled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassemia major using cardiovascular magnetic resonance
-
DOI 10.1161/CIRCULATIONAHA.106.648790
-
Tanner MA, Galanello R, Dessi C, et al. A randomized, placebo-controlled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassemia major using cardiovascular magnetic resonance. Circulation 2007; 115: 1876-84. (Pubitemid 46598901)
-
(2007)
Circulation
, vol.115
, Issue.14
, pp. 1876-1884
-
-
Tanner, M.A.1
Galanello, R.2
Dessi, C.3
Smith, G.C.4
Westwood, M.A.5
Agus, A.6
Roughton, M.7
Assomull, R.8
Nair, S.V.9
Walker, J.M.10
Pennell, D.J.11
-
52
-
-
44049102508
-
Combined chelation therapy in thalassemia major for the treatment of severe myocardial siderosis with left ventricular dysfunction
-
Tanner MA, Galanello R, Dessi C, et al. Combined chelation therapy in thalassemia major for the treatment of severe myocardial siderosis with left ventricular dysfunction. J Cardiovasc Magn Reson 2008; 10: 12.
-
(2008)
J Cardiovasc Magn Reson
, vol.10
, pp. 12
-
-
Tanner, M.A.1
Galanello, R.2
Dessi, C.3
-
53
-
-
79957483630
-
Sequential alternating deferiprone and deferoxamine treatment compared to deferiprone monotherapy: Main findings and clinical follow-up of a large multicenter randomized clinical trial in beta-thalassemia major patients
-
Pantalone GR, Maggio A, Vitrano A, et al. Sequential alternating deferiprone and deferoxamine treatment compared to deferiprone monotherapy: main findings and clinical follow-up of a large multicenter randomized clinical trial in beta-thalassemia major patients. Hemoglobin 2011; 35: 206-16.
-
(2011)
Hemoglobin
, vol.35
, pp. 206-216
-
-
Pantalone, G.R.1
Maggio, A.2
Vitrano, A.3
-
55
-
-
33745774771
-
•, ICL670), a once-daily, orally-administered iron chelator, in comparison to deferoxamine in thalassemia patients with transfusional iron overload
-
Piga A, Galanello R, Forni GL, et al. Randomized phase II trial of deferasirox (Exjade, ICL670), a once-daily, orally-administered iron chelator, in comparison to deferoxamine in thalassemia patients with transfusional iron overload. Haematologica 2006; 91: 873-80. (Pubitemid 44023139)
-
(2006)
Haematologica
, vol.91
, Issue.7
, pp. 873-880
-
-
Piga, A.1
Galanello, R.2
Forni, G.L.3
Cappellini, M.D.4
Origa, R.5
Zappu, A.6
Donato, G.7
Bordone, E.8
Lavagetto, A.9
Zanaboni, L.10
Sechaud, R.11
Hewson, N.12
Ford, J.M.13
Opitz, H.14
Albert, D.15
-
56
-
-
0037906104
-
Safety, tolerability, and pharmacokinetics of ICL670, a new orally active iron-chelating agent in patients with transfusion-dependent iron overload due to β-thalassemia
-
Galanello R, Piga A, Alberti D, et al. Safety, tolerability, and pharmacokinetics of ICL670, a new orally active iron-chelating agent in patients with transfusion-dependent iron overload due to beta-thalassemia. J Clin Pharmacol 2003; 43: 565-72. (Pubitemid 36613115)
-
(2003)
Journal of Clinical Pharmacology
, vol.43
, Issue.6
, pp. 565-572
-
-
Galanello, R.1
Piga, A.2
Alberti, D.3
Rouan, M.-C.4
Bigler, H.5
Sechaud, R.6
-
57
-
-
38049151217
-
Relative response of patients with myelodysplastic syndromes and other transfusion-dependent anaemias to deferasirox (ICL670): A 1-yr prospective study
-
Porter J, Galanello R, Saglio G, et al. Relative response of patients with myelodysplastic syndromes and other transfusion-dependent anaemias to deferasirox (ICL670): a 1-yr prospective study. Eur J Haematol 2008; 80: 168-76.
-
(2008)
Eur J Haematol
, vol.80
, pp. 168-176
-
-
Porter, J.1
Galanello, R.2
Saglio, G.3
-
58
-
-
33846012866
-
A randomised comparison of deferasirox versus deferoxamine for the treatment of transfusional iron overload in sickle cell disease
-
DOI 10.1111/j.1365-2141.2006.06455.x
-
Vichinsky E, Onyekwere O, Porter J, et al. A randomised comparison of deferasirox versus deferoxamine for the treatment of transfusional iron overload in sickle cell disease. Br J Haematol 2007; 136: 501-8. (Pubitemid 46046309)
-
(2007)
British Journal of Haematology
, vol.136
, Issue.3
, pp. 501-508
-
-
Vichinsky, E.1
Onyekwere, O.2
Porter, J.3
Swerdlow, P.4
Eckman, J.5
Lane, P.6
Files, B.7
Hassell, K.8
Kelly, P.9
Wilson, F.10
Bernaudin, F.11
Forni, G.L.12
Okpala, I.13
Ressayre-Djaffer, C.14
Alberti, D.15
Holland, J.16
Marks, P.17
Fung, E.18
Fischer, R.19
Mueller, B.U.20
Coates, T.21
more..
-
59
-
-
70450127262
-
Efficacy and safety of deferasirox (exjade®) in pediatric patients with beta-thalassemia: Update of 4.7-year efficacy and safety form extension studies
-
abstract
-
Cappellini MD. Efficacy and safety of deferasirox (exjade®) in pediatric patients with beta-thalassemia: update of 4.7-year efficacy and safety form extension studies [abstract]. Blood 2008; 112: ABS3883.
-
(2008)
Blood
, vol.112
-
-
Cappellini, M.D.1
-
60
-
-
77950682176
-
Tailoring iron chelation by iron intake and serum ferritin: The prospective EPIC study of deferasirox in 1744 patients with transfusion- dependent anemias
-
Cappellini MD, Porter J, El-Beshlawy A, et al. Tailoring iron chelation by iron intake and serum ferritin: the prospective EPIC study of deferasirox in 1744 patients with transfusion-dependent anemias. Haematologica 2010; 95: 557-66.
-
(2010)
Haematologica
, vol.95
, pp. 557-566
-
-
Cappellini, M.D.1
Porter, J.2
El-Beshlawy, A.3
-
61
-
-
65349152022
-
Efficacy and safety of deferasirox, an oral iron chelator, in heavily iron-overloaded patients with beta-thalassaemia: The ESCALATOR study
-
Taher A, El-Beshlawy A, Elalfy MS, et al. Efficacy and safety of deferasirox, an oral iron chelator, in heavily iron-overloaded patients with beta-thalassaemia: the ESCALATOR study. Eur J Haematol 2009; 82: 458-65.
-
(2009)
Eur J Haematol
, vol.82
, pp. 458-465
-
-
Taher, A.1
El-Beshlawy, A.2
Elalfy, M.S.3
-
62
-
-
80052691105
-
Improvement in liver pathology of patients with β-thalassemia treated with deferasirox for at least 3 years
-
Deugneir Y, Turlin B, Ropert M, et al. Improvement in liver pathology of patients with β-thalassemia treated with deferasirox for at least 3 years. Gastroenterology 2011; 141: 1202-11, 1211.e1-3.
-
(2011)
Gastroenterology
, vol.141
-
-
Deugneir, Y.1
Turlin, B.2
Ropert, M.3
-
63
-
-
78650996705
-
Continued improvement in myocardial T2*over two years of deferasirox therapy in β-thalassemia major patients with cardiac iron overload
-
Pennell DJ, Porter JB, Cappellini MD, et al. Continued improvement in myocardial T2*over two years of deferasirox therapy in β-thalassemia major patients with cardiac iron overload. Haematologica. 2011; 96: 48-54.
-
(2011)
Haematologica.
, vol.96
, pp. 48-54
-
-
Pennell, D.J.1
Porter, J.B.2
Cappellini, M.D.3
-
64
-
-
77957314807
-
Safety of combined chelation therapy with deferasirox and deferoxaminein transfusion-dependent thalassemia
-
Abstract
-
Lal L. Safety of combined chelation therapy with deferasirox and deferoxaminein transfusion-dependent thalassemia [Abstract]. Blood 2009; 114: 2021.
-
(2009)
Blood
, vol.114
, pp. 2021
-
-
Lal, L.1
-
65
-
-
56149116825
-
Safety and efficacy of combined chelation therapy with deferasirox and deferoxamine in a gerbil model of iron overload
-
Otto-Duessel M, Brewer C, Gonzalez I, Nick H, Wood JC. Safety and efficacy of combined chelation therapy with deferasirox and deferoxamine in a gerbil model of iron overload. Acta Haematol 2008; 120: 123-8.
-
(2008)
Acta Haematol
, vol.120
, pp. 123-128
-
-
Otto-Duessel, M.1
Brewer, C.2
Gonzalez, I.3
Nick, H.4
Wood, J.C.5
-
66
-
-
58949098317
-
Reversal of iron-induced dilated cardiomyopathy during therapy with deferasirox in beta-thalassemia
-
Trad O, Hamdan MA, Jamil A, et al. Reversal of iron-induced dilated cardiomyopathy during therapy with deferasirox in beta-thalassemia. Pediatr Blood Cancer 2009; 52: 426-8.
-
(2009)
Pediatr Blood Cancer
, vol.52
, pp. 426-428
-
-
Trad, O.1
Hamdan, M.A.2
Jamil, A.3
-
68
-
-
0035138693
-
Deferoxamine pharmacokinetics
-
Porter JB. Deferoxamine pharmacokinetics. Semin Haematol 2001; 38 (1 Suppl 1): 63-8. (Pubitemid 32110273)
-
(2001)
Seminars in Hematology
, vol.38
, Issue.1 SUPPL. 1
, pp. 63-68
-
-
Porter, J.B.1
-
69
-
-
0028962119
-
Pharmacokinetics of the oral iron chelator deferiprone (L1) in patients with iron overload
-
al-Refaie FN, Sheppard LN, Nortey P, et al. Pharmacokinetics of the oral iron chelator deferiprone (L1) in patients with iron overload. Br J Haematol 1995; 89: 403-8.
-
(1995)
Br J Haematol
, vol.89
, pp. 403-408
-
-
Al-Refaie, F.N.1
Sheppard, L.N.2
Nortey, P.3
-
70
-
-
14544271816
-
LPI-labile plasma iron in iron overload
-
DOI 10.1016/j.beha.2004.10.003, PII S1521692604001264
-
Cabantchick ZI, Breuer W, Zanninelli G, Cianciulli P. LPI-labile plasma iron in iron overload. Best Pract Res Clin Haematol 2005; 18: 277-87. (Pubitemid 40298370)
-
(2005)
Best Practice and Research: Clinical Haematology
, vol.18
, Issue.2 SPEC. ISS.
, pp. 277-287
-
-
Cabantchik, Z.I.1
Breuer, W.2
Zanninelli, G.3
Cianciulli, P.4
-
71
-
-
74049116227
-
Normalisation of total body iron load with very intensive combined chelation reverses cardiac and endocrine complications of thalassaemia major
-
Farmaki K, Tzoumari I, Pappa C, Chouliaras G, Berdoukas V. Normalisation of total body iron load with very intensive combined chelation reverses cardiac and endocrine complications of thalassaemia major. Br J Haematol 2010; 148: 466-75.
-
(2010)
Br J Haematol
, vol.148
, pp. 466-475
-
-
Farmaki, K.1
Tzoumari, I.2
Pappa, C.3
Chouliaras, G.4
Berdoukas, V.5
-
72
-
-
65349110837
-
Reduction in labile plasma iron during treatment with deferasirox, a oncedaily oral iron chelator, in heavily iron-overloaded patients with beta-thalassaemia
-
Daar S, Pathare A, Nick H, et al. Reduction in labile plasma iron during treatment with deferasirox, a oncedaily oral iron chelator, in heavily iron-overloaded patients with beta-thalassaemia. Eur J Haematol 2009; 82: 454-7.
-
(2009)
Eur J Haematol
, vol.82
, pp. 454-457
-
-
Daar, S.1
Pathare, A.2
Nick, H.3
-
73
-
-
79961008228
-
Iron chelation with deferasirox in adult and pediatric patients with thalassemia major: Efficacy and safety during 5 years' follow-up
-
Cappellini MD, Bejaoui M, Agaoglu L, et al. Iron chelation with deferasirox in adult and pediatric patients with thalassemia major: efficacy and safety during 5 years' follow-up. Blood 2011; 118: 884-93.
-
(2011)
Blood
, vol.118
, pp. 884-893
-
-
Cappellini, M.D.1
Bejaoui, M.2
Agaoglu, L.3
-
74
-
-
43449119849
-
Complete hematopoietic recovery after continuous iron chelation therapy in a patient with severe aplastic anemia with secondary hemochromatosis
-
Park SJ, Han CW. Complete hematopoietic recovery after continuous iron chelation therapy in a patient with severe aplastic anemia with secondary hemochromatosis. J Korean Med Sci 2008; 23: 320-3.
-
(2008)
J Korean Med Sci
, vol.23
, pp. 320-323
-
-
Park, S.J.1
Han, C.W.2
-
75
-
-
77955268192
-
Deferasirox in iron-overloaded patients with transfusiondependent myelodysplastic syndromes: Results from the large 1-year EPIC study
-
Gattermann N, Arisch A, Schlag R, et al. Deferasirox in iron-overloaded patients with transfusiondependent myelodysplastic syndromes: results from the large 1-year EPIC study. Leuk Res 2010; 34: 1143-50.
-
(2010)
Leuk Res
, vol.34
, pp. 1143-1150
-
-
Gattermann, N.1
Arisch, A.2
Schlag, R.3
-
76
-
-
38349157810
-
Effect of transfusional iron intake on response to chelation therapy in betathalassemia major
-
Cohen AR, Glimm E, Porter JB. Effect of transfusional iron intake on response to chelation therapy in betathalassemia major. Blood 2008; 111: 583-7.
-
(2008)
Blood
, vol.111
, pp. 583-587
-
-
Cohen, A.R.1
Glimm, E.2
Porter, J.B.3
-
77
-
-
80053222965
-
Response of iron overload to deferasirox in rare transfusion-dependent anaemias: Equivalent effects on serum ferritin and labile plasma iron for haemolytic or production anaemias
-
Porter JB, Lin KH, Beris P, et al. Response of iron overload to deferasirox in rare transfusion-dependent anaemias: equivalent effects on serum ferritin and labile plasma iron for haemolytic or production anaemias. Eur J Haematol 2011; 87: 338-48.
-
(2011)
Eur J Haematol
, vol.87
, pp. 338-348
-
-
Porter, J.B.1
Lin, K.H.2
Beris, P.3
-
78
-
-
77952956043
-
Matched-pair analysis of 186 MDS patients receiving iron chelation therapy or transfusion therapy only
-
abstract
-
Fox F. Matched-pair analysis of 186 MDS patients receiving iron chelation therapy or transfusion therapy only [abstract]. Blood 2009; 114 (22): ABS1747.
-
(2009)
Blood
, vol.114
, Issue.22
-
-
Fox, F.1
-
79
-
-
70449715018
-
Improved survival in patients with myelodysplastic syndrome receiving iron chelation therapy
-
Leitch HA, Chase JM, Goodman TA, et al. Improved survival in patients with myelodysplastic syndrome receiving iron chelation therapy. Clin Leukemia 2008; 2: 205-11.
-
(2008)
Clin Leukemia
, vol.2
, pp. 205-211
-
-
Leitch, H.A.1
Chase, J.M.2
Goodman, T.A.3
-
80
-
-
77952959079
-
Does iron chelation therapy improve survival in regularly transfused lower risk MDS patients? A multicenter study by the GFM (Groupe Francophone des Myélodysplasies)
-
Rose C, Brechignac S, Vassilief D, et al. Does iron chelation therapy improve survival in regularly transfused lower risk MDS patients? A multicenter study by the GFM (Groupe Francophone des Myélodysplasies). Leuk Res 2010; 34: 864-70.
-
(2010)
Leuk Res
, vol.34
, pp. 864-870
-
-
Rose, C.1
Brechignac, S.2
Vassilief, D.3
-
81
-
-
66349122329
-
Independent impact of iron overload and transfusion dependency on survival and leukemic evolution in patients with myelodysplastic syndrome
-
abstract
-
Sanz G. Independent impact of iron overload and transfusion dependency on survival and leukemic evolution in patients with myelodysplastic syndrome [abstract]. Blood 2008; 112 (II): ABS640.
-
(2008)
Blood
, vol.112
, Issue.2
-
-
Sanz, G.1
-
82
-
-
77955268192
-
Deferasirox in iron-overloaded patients with transfusion-dependent myelodysplastic syndromes: Results from the large 1-year EPIC study
-
Gattermann N, Finelli C, Porta MD, et al. Deferasirox in iron-overloaded patients with transfusion-dependent myelodysplastic syndromes: results from the large 1-year EPIC study. Leuk Res 2010; 34: 1143-50.
-
(2010)
Leuk Res
, vol.34
, pp. 1143-1150
-
-
Gattermann, N.1
Finelli, C.2
Porta, M.D.3
-
83
-
-
77954338182
-
Iron chelation therapy associated with improvement of hematopoiesis in transfusion-dependent patients
-
Oliva EN, Ronco F, Marino A, et al. Iron chelation therapy associated with improvement of hematopoiesis in transfusion-dependent patients. Transfusion 2010; 50: 1568-70.
-
(2010)
Transfusion
, vol.50
, pp. 1568-1570
-
-
Oliva, E.N.1
Ronco, F.2
Marino, A.3
-
84
-
-
77954253063
-
Deferasirox treatment interruption in a transfusion-requiring myelodysplastic patient led to loss of erythroid response
-
Breccia M, Loglisci G, Saiaroli A, et al. Deferasirox treatment interruption in a transfusion-requiring myelodysplastic patient led to loss of erythroid response. Acta Haematol 2010; 24: 46-8.
-
(2010)
Acta Haematol
, vol.24
, pp. 46-48
-
-
Breccia, M.1
Loglisci, G.2
Saiaroli, A.3
-
85
-
-
79960398677
-
Hematologic responses in myelodysplastic syndrome (MDS) patients treated with deferasirox: An EPIC post-hoc analysis using International Working Group (IWG) 2006 criteria
-
abstract
-
Gattermann N. Hematologic responses in myelodysplastic syndrome (MDS) patients treated with deferasirox: an EPIC post-hoc analysis using International Working Group (IWG) 2006 criteria [abstract]. Blood 2010; 116 (21): ABS2912.
-
(2010)
Blood
, vol.116
, Issue.21
-
-
Gattermann, N.1
-
86
-
-
84870009822
-
Independent impact of iron overload and transfusion dependency on survival and leukemic evolution in patients with myelodysplastic syndrome
-
abstract
-
Molteni A. Independent impact of iron overload and transfusion dependency on survival and leukemic evolution in patients with myelodysplastic syndrome [abstract]. Haematologica 2010; 95 (Suppl 2): ABS640.
-
(2010)
Haematologica
, vol.95
, Issue.SUPPL. 2
-
-
Molteni, A.1
-
87
-
-
33746378606
-
Mild dehydrated hereditary stomatocytosis revealed by marked hepatosiderosis
-
DOI 10.1111/j.1365-2257.2006.00774.x
-
Syfuss PY, Ciupea A, Brahimi S, et al. Mild dehydrated hereditary stomatocytosis revealed by marked hepatosiderosis. Clin Lab Haematol 2006; 28: 270-4. (Pubitemid 44114642)
-
(2006)
Clinical and Laboratory Haematology
, vol.28
, Issue.4
, pp. 270-274
-
-
Syfuss, P.-Y.1
Ciupea, A.2
Brahimi, S.3
Cynober, T.4
Stewart, G.W.5
Grandchamp, B.6
Beaumont, C.7
Tchernia, G.8
Delaunay, J.9
Wagner, J.-C.10
-
88
-
-
33645717043
-
Iron Overload Manifesting as Apparent Exacerbation of Hepatic Graft-versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation
-
DOI 10.1016/j.bbmt.2006.01.004, PII S1083879106000449
-
Kamble RT, Selby GB, Mims M, et al. Iron overload manifesting as apparent exacerbation of hepatic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2006; 12: 506-10. (Pubitemid 43964819)
-
(2006)
Biology of Blood and Marrow Transplantation
, vol.12
, Issue.5
, pp. 506-510
-
-
Kamble, R.T.1
Selby, G.B.2
Mims, M.3
Kharfan-Dabaja, M.A.4
Ozer, H.5
George, J.N.6
-
89
-
-
0030042633
-
Iron overload and liver dysfunction after allogeneic or autologous bone marrow transplantation
-
Mckay PJ, Murphy JA, Cameron S, et al. Iron overload and liver dysfunction after allogeneic or autologous bone marrow transplantation. Bone Marrow Transplant 1996; 17: 63-6. (Pubitemid 26031892)
-
(1996)
Bone Marrow Transplantation
, vol.17
, Issue.1
, pp. 63-66
-
-
McKay, P.J.1
Murphy, J.A.2
Cameron, S.3
Burnett, A.K.4
Campbell, M.5
Tansey, P.6
Franklin, I.M.7
-
90
-
-
0027184519
-
Marrow transplantation in patients with thalassemia responsive to iron chelation therapy
-
DOI 10.1056/NEJM199309163291204
-
Lucarelli G, Galimberti M, Polchi P, et al. Marrow transplantation in patients with thalassemia responsive to iron chelation therapy. N Engl J Med 1993; 329: 840-4. (Pubitemid 23267211)
-
(1993)
New England Journal of Medicine
, vol.329
, Issue.12
, pp. 840-844
-
-
Lucarelli, G.1
Galimberti, M.2
Polchi, P.3
Angelucci, E.4
Baronciani, D.5
Giardini, C.6
Andreani, M.7
Agostinelli, F.8
Albertini, F.9
Clift, R.A.10
-
91
-
-
33645724771
-
Iron-overload in long-term survivors of hematopoietic transplantation
-
Kamble R, Mims M. Iron-overload in long-term survivors of hematopoietic transplantation. Bone Marrow Transplant 2006; 37: 805-6.
-
(2006)
Bone Marrow Transplant
, vol.37
, pp. 805-806
-
-
Kamble, R.1
Mims, M.2
-
92
-
-
0242636489
-
Autografting as a risk factor for persisting iron overload in long-term survivors of acute myeloid leukaemia
-
DOI 10.1038/sj.bmt.1704244
-
Butt NM, Clark RE. Autografting as a risk factor for persisting iron overload in long-term survivors of acute myeloid leukaemia. Bone Marrow Transplant 2003; 32: 909-13. (Pubitemid 37369269)
-
(2003)
Bone Marrow Transplantation
, vol.32
, Issue.9
, pp. 909-913
-
-
Butt, N.M.1
Clark, R.E.2
-
93
-
-
33646049725
-
Iron overload is a major risk factor for severe infection after autologous stem cell transplantation: A study of 367 myeloma patients
-
Miceli MH, Dong L, Grazziutti ML, et al. Iron overload is a major risk factor for severe infection after autologous stem cell transplantation: a study of 367 myeloma patients. Bone Marrow Transplant 2006; 37: 857-64.
-
(2006)
Bone Marrow Transplant
, vol.37
, pp. 857-864
-
-
Miceli, M.H.1
Dong, L.2
Grazziutti, M.L.3
-
94
-
-
0034006995
-
Serum ferritin as risk factor for veno-occlusive disease of the liver. Prospective cohort study
-
Morado M, Ojeda E, Garcia-Bustos J, et al. BMT: Serum ferritin as risk factor for veno-occlusive disease of the liver. Prospective cohort study. Hematology 2000; 4: 505-12. (Pubitemid 30217860)
-
(2000)
Hematology
, vol.4
, Issue.6
, pp. 505-512
-
-
Morado, M.1
Ojeda, E.2
Garcia-Bustos, J.3
Aguado, M.J.4
Arrieta, R.5
Quevedo, E.6
Navas, A.7
Hernandez-Navarro, F.8
-
95
-
-
43049167385
-
Iron overload in myelodysplastic syndromes: A Canadian consensus guideline
-
Wells RA, Leber B, Buckstein R, et al. Iron overload in myelodysplastic syndromes: a Canadian consensus guideline. Leukemia Res 2008; 32: 1338-53.
-
(2008)
Leukemia Res
, vol.32
, pp. 1338-1353
-
-
Wells, R.A.1
Leber, B.2
Buckstein, R.3
-
96
-
-
36849075284
-
Iron chelation beyond transfusion iron overload
-
DOI 10.1002/ajh.21101
-
Pietrangelo A. Iron chelation beyond transfusion iron overload. Am J Hematol 2007; 82 (12 Suppl): 1142-6. (Pubitemid 350221246)
-
(2007)
American Journal of Hematology
, vol.82
, Issue.12 SUPPL.
, pp. 1142-1146
-
-
Pietrangelo, A.1
-
97
-
-
37749054933
-
Effect of an oral iron chelator or iron-deficient diets on uroporphyria in a murine model of porphyria cutanea tarda
-
Gorman N, Zaharia A, Trask HS, et al. Effect of an oral iron chelator or iron-deficient diets on uroporphyria in a murine model of porphyria cutanea tarda. Hepatology 2007; 46: 1927-34.
-
(2007)
Hepatology
, vol.46
, pp. 1927-1934
-
-
Gorman, N.1
Zaharia, A.2
Trask, H.S.3
-
98
-
-
34848831462
-
The iron chelator deferasirox protects mice from mucormycosis through iron starvation
-
DOI 10.1172/JCI32338
-
Ibrahim AS, Gebermariam T, Fu Y, et al. The iron chelator deferasirox protects mice from mucormycosis through iron starvation. J Clin Invest 2007; 117: 2649-57. (Pubitemid 47494365)
-
(2007)
Journal of Clinical Investigation
, vol.117
, Issue.9
, pp. 2649-2657
-
-
Ibrahim, A.S.1
Gebermariam, T.2
Fu, Y.3
Lin, L.4
Husseiny, M.I.5
French, S.W.6
Schwartz, J.7
Skory, C.D.8
Edwards Jr., J.E.9
Spellberg, B.J.10
-
99
-
-
80051615717
-
Deferoxamine for advanced hepatocellular carcinoma
-
Yamasaki T, Terai S, Sakaida I. Deferoxamine for advanced hepatocellular carcinoma. N Engl J Med 2011; 365: 576-8.
-
(2011)
N Engl J Med
, vol.365
, pp. 576-578
-
-
Yamasaki, T.1
Terai, S.2
Sakaida, I.3
-
100
-
-
79953853812
-
A phase I dose-escalation study: Safety, tolerability, and pharmacokinetics of FBS070I, a novel iron chelator for the treatment of transfusional iron overload
-
Rienhoff HY Jr, Viprakasit V, Tay L, et al. A phase I dose-escalation study: safety, tolerability, and pharmacokinetics of FBS070I, a novel iron chelator for the treatment of transfusional iron overload. Haematologica 2010; 96: 521-5.
-
(2010)
Haematologica
, vol.96
, pp. 521-525
-
-
Rienhoff Jr., H.Y.1
Viprakasit, V.2
Tay, L.3
-
101
-
-
84859604828
-
A phase 2 study of the safety, tolerability and pharmacodynamics of FBS0701, a novel oral iron chelator, in transfusional iron overload
-
Neufeld EJ, Galanello R, Viprakasit V, et al. A phase 2 study of the safety, tolerability and pharmacodynamics of FBS0701, a novel oral iron chelator, in transfusional iron overload. Blood 2012; 119: 3263-8.
-
(2012)
Blood
, vol.119
, pp. 3263-3268
-
-
Neufeld, E.J.1
Galanello, R.2
Viprakasit, V.3
|